TSG-6: An IL-1/TNF-inducible protein with anti-inflammatory activity

Cytokine and Growth Factor Reviews

Volumn 8, Issue 2, 1997, Pages 143-156

  Wisniewski, Hans Georg ^a   Vilček, Jan ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

CUB domain; Extracellular matrix degradation; Hyaladherins; Inflammation; Inter inhibitor; TSG 6

Indexed keywords

ANTIINFLAMMATORY AGENT; CELL ADHESION MOLECULE; CYTOKINE; HYALURONIC ACID; INTERLEUKIN 1; PROTEIN; TSG-6 PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ANTIINFLAMMATORY ACTIVITY; BINDING SITE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; METABOLISM; NONHUMAN; PHYSIOLOGY; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION;

ANIMALIA; MAMMALIA; MURINAE;

EID: 0343742633     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(97)00008-7     Document Type: Short Survey

References (135)

1. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994, 15, 74-80.
2. Krönke M, Schütze S, Scheurich P, Pfizenmaier K. TNF signal transduction and TNF-responsive genes. In Tumor Necrosis Factors: Structure, Function, and Mechanism of Action, eds B. B. Aggarwal and J. Vilček. Marcel Dekker Inc., New York, 1992.
3. Lee TH, Lee GW, Ziff EB, Vilček J. Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts. Mol Cell Biol 1990, 10, 1982-1988.
4. Feng P, Liau G. Identification of a novel serum and growth factor-inducible gene in vascular smooth muscle cells [erratum in J Biol Chem 1993, 268, 21453]. J Biol Chem 1993, 268, 9387-9392.
5. Lee TH, Wisniewski H-G, Vilček J. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J Cell Biol 1992, 116, 545-557.
6. Wisniewski H-G, Maier R, Lotz M, Lee S, Klampfer L, Lee TH, Vilček J. TSG-6: a TNF-, IL-1-, and LPS-inducible secreted glycoprotein associated with arthritis. J Immunol 1993, 151, 6593-6601.
7. Lotz M, Kekow J, Carson DA. Transforming growth factor-beta and cellular immune responses in synovial fluids. J Immunol 1990, 144, 4189-4194.
8. Miossec P, Naviliat M, Dupuy d'Angeac A, Sany J, Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arth Rheum 1990, 33, 1180-1187.
9. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992, 89, 7375-7379.
10. Maier R, Wisniewski H-G, Vilček J, Lotz M. TSG-6 expression in human articular chondrocytes: possible implications in joint inflammation and cartilage degradation. Arth Rheum 1996, 39, 552-559.
11. Lee TH, Wisniewski H-G, Klampfer L, Oppenheim JD, Vilček J. TSG-6: A novel secretory protein inducible by tumor necrosis factor or interleukin-1 in fibroblasts and mononuclear cells. In Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance, eds W. Fiers and W. A. Buurman, S. Karger, Basel, 1993, pp. 90-95.
12. Kohda D, Morton CJ, Parkar AA, Hatanaka H, Inagaki FM, Campbell ID, Day AJ. Solution structure of the link module: A hyaluronan-binding domain involved in extracellular matrix stability and cell migration. Cell 1996, 86, 767-775.
13. Toole BP. Hyaluronan and its binding proteins, the hyaladherins. Curr Opin Cell Biol 1990, 2, 839-844.
14. Toole BP, Proteoglycans and hyaluronan in morphogenesis and differentiation. In Cell Biology and Extracellular Matrix, ed. E. D. Hay. Plenum Press, New York, 1992, pp. 305-341.
15. Iozzo RV, Murdoch AD. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 1996, 10, 598-614.
16. Bork P, Beckmann G. The CUB domain. A widespread module in developmentally regulated proteins. J Mol Biol 1993, 231, 539-545.
17. Delgadillo-Reynoso MG, Rollo DR, Hursh DA, Raff RA. Structural analysis of the uEGF gene in the sea urchin strongylocentrotus purpuratus reveals more similarity to vertebrate than to invertebrate genes with EGF-like repeats. J Mol Evol 1989, 29, 314-327.
18. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242, 1528-1534.
19. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS. Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science 1996, 271, 360-362.
20. Bork P, Holm L, Sander C. The immunoglobulin fold. Structural classification, sequence patterns and common core. J Mol Biol 1994, 242, 309-320.
21. Romero A, Varela PF, Sanz L, Topfer-Petersen E, Calvete JJ. Crystallization and preliminary X-ray diffraction analysis of boar seminal plasma spermadhesin PSP-I/PSP-II, a heterodimer of two CUB domains. FEBS Lett 1996, 382, 15-17.
22. Sanz L, Calvete JJ, Mann K, Gabius HJ, Topfer-Petersen E. Isolation and biochemical characterization of heparin-binding proteins from boar seminal plasma: a dual role for spermadhesins in fertilization. Mol Reprod Dev 1993, 35, 37-43.
23. Calvete JJ, Sanz L, Dostalova Z, Topfer-Petersen E. Characterization of AWN-1 glycosylated isoforms helps define the zona pellucida and serine proteinase inhibitor-binding region on boar spermadhesins. FEBS Lett 1993, 334, 37-40.
24. Sanz L, Calvete JJ, Schafer W, Mann K, Topfer-Petersen E. Isolation and biochemical characterization of two isoforms of a boar sperm zona pellucida-binding protein. Biochim Biophys Acta 1992, 1119, 127-132.
25. Dostalova Z, Calvete JJ, Sanz L, Topfer-Petersen E. Boar spermadhesin AWN-1. Oligosaccharide and zona pellucida binding characteristics. Eur J Biochem 1995, 230, 329-336.
26. Sanz L, Calvete JJ, Jonakova V, Topfer-Petersen E. Boar spermadhesins AQN-1 and AWN are sperm-associated acrosin inhibitor acceptor proteins. FEBS Lett 1992, 300, 63-66.
27. Calvete JJ, Dostalova Z, Sanz L, Adermann K, Thole HH, Topfer-Petersen E. Mapping the heparin-binding domain of boar spermadhesins. FEBS Lett 1996, 379, 207-211.
28. Lee TH, Klampfer L, Shows TB, Vilček J. Transcriptional regulation of TSG6, a tumor necrosis factor- and interleukin-1-inducible primary response gene coding for a secreted hyaluronan-binding protein. J Biol Chem 1993, 268, 6154-6160.
29. Klampfer L, Lee TH, Hsu W, Vilček J, Chen-Kiang S. NF-IL6 and AP-1 cooperatively modulate the activation of the TSG-6 gene by tumor necrosis factor alpha and interleukin-1. Mol Cell Biol 1994, 14, 6561-6569.
30. Klampfer L, Chen-Kiang S, Vilček J. Activation of the TSG-6 gene by NF-IL6 requires two adjacent NF-IL6 binding sites. J Biol Chem 1995, 270, 3677-3682.
31. Guerne PA, Carson DA, Lotz M. IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol 1990, 144, 499-505.
32. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Brit J Rheumatol 1992, 31, 653-661.
33. Doege K, Hassell JR, Caterson B, Yamada Y. Link protein cDNA sequence reveals a tandemly repeated protein structure. Proc Natl Acad Sci USA 1986, 83, 3761-3765.
34. Goetinck PF, Stirpe NS, Tsonis PA, Carlone D. The tandemly repeated sequences of cartilage link protein contain the sites for interaction with hyaluronic acid. J Cell Biol 1987, 105, 2403-2408.
35. LeBaron RG, Zimmermann DR, Ruoslahti E. Hyaluronate binding properties of versican. J Biol Chem 1992, 267, 10003-10010.
36. Binette F, Cravens J, Kahoussi B, Haudenschild DR, Goetinck PF. Link protein is ubiquitously expressed in noncartilaginous tissues where it enhances and stabilizes the interaction of proteoglycans with hyaluronic acid. J Biol Chem 1994, 269, 19116-19122.
37. Grover J, Roughley PJ. The expression of functional link protein in a baculovirus system: analysis of mutants lacking the A, B and B' domains. Biochem J 1994, 300, 317-324.
38. Varelas JB, Kollar J, Huynh TD, Hering TM. Expression and characterization of a single recombinant proteoglycan tandem repeat domain of link protein that binds zinc and hyaluronate. Arch Biochem & Biophys 1995, 321, 21-30.
39. Morgelin M, Paulsson M, Hardingham TE, Heinegard D, Engel J. Cartilage proteoglycans. Assembly with hyaluronate and link protein as studied by electron microscopy. Biochem J 1988, 253, 175-185.
40. Fosang AJ, Hey NJ, Carney SL, Hardingham TE. An ELISA plate-based assay for hyaluronan using biotinylated proteoglycan G1 domain (HA-binding region). Matrix 1990, 10, 306-313.
41. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 1993, 122, 257-264.
42. Yang B, Yang BL, Savani RC, Turley EA. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J 1994, 13, 286-296.
43. Scott JE. Secondary structures in hyaluronan solutions: chemical and biological implications. In The Biology of Hyaluronan, eds D. Evered and J. Whelan. John Wiley and Sons, Chichester, 1989, pp. 6-15.
44. Turley EA, Austen L, Vandeligt K, Clary C. Hyaluronan and a cell-associated hyaluronan binding protein regulate the locomotion of ras-transformed cells. J Cell Biol 1991, 112, 1041-1047.
45. Hardwick C, Hoare K, Owens R, Hohn HP, Hook M, Moore D, Cripps V, Austen L, Nance DM, Turley EA. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility [published erratum appears in J Cell Biol 1992, Aug, 118(3), 753]. J Cell Biol 1992, 117, 1343-1350.
46. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA, Greenberg AH. TGF-β1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. J Cell Biol 1993, 123, 749-758.
47. Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 1993, 7, 1233-1241.
48. Knudson CB, Munaim SI, Toole BP. Ectodermal stimulation of the production of hyaluronan-dependent pericellular matrix by embryonic limb mesodermal cells. Dev Dynamics 1995, 204, 186-191.
49. Maleski MP, Knudson CB. Hyaluronan-mediated aggregation of limb bud mesenchyme and mesenchymal condensation during chondrogenesis. Exp Cell Res 1996, 225, 55-66.
50. Pauli BU, Knudson W. Tumor invasion: a consequence of destructive and compositional matrix alterations. Human Pathol 1988, 19, 628-639.
51. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Amer J Pathol 1996, 148, 1721-1726.
52. Toole BP, Biswas C, Gross J. Hyaluronate and invasiveness of the rabbit V2 carcinoma. Proc Natl Acad Sci USA 1979, 76, 6299-6303.
53. Knudson W, Biswas C, Toole BP. Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci USA 1984, 81, 6767-6771.
54. King SR, Hickerson WL, Proctor KG. Beneficial actions of exogenous hyaluronic acid on wound healing. Surgery 1991, 109, 76-84.
55. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985, 228, 1324-1326.
56. Postlethwaite AE, Smith GN Jr, Lachman LB, Endres RO, Poppleton HM, Hasty KA, Seyer JM, Kang AH. Stimulation of glycosaminoglycan synthesis in cultured human dermal fibroblasts by interleukin 1. Induction of hyaluronic acid synthesis by natural and recombinant interleukin 1s and synthetic interleukin 1 β peptide 163-171. J Clin Invest 1989, 83, 629-636.
57. Butler DM, Vitti GF, Leizer T, Hamilton JA. Stimulation of the hyaluronic acid levels of human synovial fibroblasts by recombinant human tumor necrosis factor α, tumor necrosis factor β (lymphotoxin), interleukin-1 α, and interleukin-1 β. Arth Rheum 1988, 31, 1281-1289.
58. Wells AF, Klareskog L, Lindblad S, Laurent TC. Correlation between increased hyaluronan localized in arthritic synovium and the presence of proliferating cells. A role for macrophage-derived factors. Arth Rheum 1992, 35, 391-396.
59. Worrall JG, Bayliss MT, Edwards JCW. Morphological localization of hyaluronan in normal and diseased synovium. J Rheum 1991, 18, 1466-1472.
60. Mikecz K, Brennan FR, Kim JH, Glant TT. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nature Med 1995, 1, 558-563.
61. Wisniewski H-G, Lee TH, Lee S. Vilček J. TSG-6: A TNF-and IL-1-inducible 39 kD hyaluronate binding protein with homology to the cartilage link protein family. In Physiology and Pathophysiology of Cytokines, eds A. Mantovani and P. Ghezzi. Biomedical Press, Augusta, GA, 1992, pp. 149-155.
62. Wisniewski H-G, Burgess WH, Oppenheim JD, Vilček J. TSG-6, an arthritis-associated hyaluronan binding protein, forms a stable complex with the serum protein inter-α-inhibitor. Biochemistry 1994, 33, 7423-7429.
63. 2-globulin from human plasma. Nature 1961, 192, 1196.
64. Heide K, Heimburger N, Haupt H. Clin Chem Acta 1965, 11, 82-85.
65. Salier JP, Rouet P, Raguenez G, Daveau M. The inter-α-inhibitor family: from structure to regulation. Biochem J 1996, 315, 1-9.
66. Enghild JJ, Thøgersen IB, Pizzo SV, Salvesen G. Analysis of inter-α-trypsin inhibitor and a novel trypsin inhibitor, pre-α-trypsin inhibitor, from human plasma. Polypeptide chain stoichiometry and assembly by glycan. J Biol Chem 1989, 264, 15975-15981.
67. Gebhard W, Schreitmfller T, Hochstrasser K, Wachter E. Two out of the three kinds of subunits of inter-a-trypsin inhibitor are structurally related. Eur J Biochem 1989, 181, 571-576.
68. Gebhard W, Hochstrasser K, Fritz H, Enghild JJ, Pizzo SV, Salvesen G. Structure of inter-α-inhibitor (inter-α-trypsin inhibitor) and pre-α-inhibitor: current state and proposition of a new terminology. Biol Chem Hoppe-Seyler 1990, 371, 13-22.
69. Jessen TE, Faarvang KL, Ploug M. Carbohydrate as covalent crosslink in human inter-α-trypsin inhibitor: a novel plasma protein structure. FEBS Lett 1988, 230, 195-200.
70. Balduyck M, Laroui S, Mizon C, Mizon J. A proteoglycan related to the urinary trypsin inhibitor (UTI) links the two heavy chains of inter-α-trypsin inhibitor. Biol Chem Hoppe-Seyler 1989, 370, 329-336.
71. Enghild JJ, Salvesen G, Thøgersen IB, Valnickova Z, Pizzo SV, Hefta SA. Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-α-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. J Biol Chem 1993, 268, 8711-8716.
72. Enghild JJ, Salvesen G, Hefta SA, Thøgersen IB, Rutherfurd S, Pizzo SV. Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-α-inhibitor. J Biol Chem 1991, 266, 747-751.
73. Chirat F, Balduyck M, Mizon C, Laroui S, Sautiere P, Mizon J. A chondroitin-sulfate chain is located on serine-10 of the urinary trypsin inhibitor. Int J Biochem 1991, 23, 1201-1203.
74. Daveau M, Rouet P, Scotte M, Faye L, Hiron M, Lebreton J-P, Salier J-P. Human inter-α-inhibitor family in inflammation: simultaneous synthesis of positive and negative acute-phase proteins. Biochem J 1993, 292, 485-492.
75. Becker A, Sandson J. The source of the inter-α trypsin inhibitor in pathologic hyaluronateprotein. Arth Rheum 1971, 14, 764-766.
76. Hutadilok N, Ghosh P, Brooks PM. Binding of haptoglobin, inter-α-trypsin inhibitor, and α 1 proteinase inhibitor to synovial fluid hyaluronate and the influence of these proteins on its degradation by oxygen derived free radicals. Ann Rheum Dis 1988, 47, 377-385.
77. Brackertz D, Hagmann J, Kueppers F. Proteinase inhibitors in rheumatoid arthritis. Ann Rheum Dis 1975, 34, 225-230.
78. Jessen TE, Odum L, Johnsen AH. In vivo binding of human inter-alpha-trypsin inhibitor free heavy chains to hyaluronic acid. Biol Chem Hoppe-Sevler 1994, 375, 521-526.
79. Potempa J, Kwon K, Chawla R, Travis J. Inter-α-trypsin inhibitor. Inhibition spectrum of native and derived forms. J Biol Chem 1989, 264, 15109-15114.
80. Bieth JG. Pathophysiological interpretation of kinetic constants of protease inhibitors. Bull Europ Physiopath Resp 1980, 16, 183-197.
81. Wisniewski H-G, Hua J-C, Poppers DM, Naime D, Vilček J, Cronstein BN. TNF/IL-1-inducible protein TSG-6 potentiates plasmin inhibition by inter-α-inhibitor and exerts a strong anti-inflammatory effect in vivo. J Immunol 1996, 156, 1609-1615.
82. Opdenakker G, Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine 1992, 4, 251-258.
83. Weiss SJ. Tissue destruction by neutrophils. New Eng J Med 1989, 320, 365-376.
84. Cawston TE. Proteinases and inhibitors. British Medical Bulletin 1995, 51, 385-401.
85. Poole AR, Alini M, Hollander AP. Cellular biology of cartilage degradation. In Mechanisms and Models in Rheumatoid Arthritis, eds B. Henderson, J. C. W. Edwards and E. R. Pettipher. Academic Press, London, 1995, pp. 163-204.
86. Werb Z, Banda MJ, Jones PA. Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages. J Exp Med 1980, 152, 1340-1357.
87. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Ann Rev Cell Biol 1988, 4, 93-126.
88. Blasi F. Molecular mechanisms of protease-mediated tumor invasiveness. J Surg Oncol Suppl 1993, 3, 21-23.
89. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995, 9, 939-945.
90. Zagorski J, Wahl SM. Growth factors in the pathogenesis of rheumatoid arthritis. In Mechanisms and models in rheumatoid arthritis, eds B. Henderson, J. C. W. Edwards and E. R. Pettipher. Academic Press, London, 1995, pp. 243-259.
91. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 1989, 109, 309-315.
92. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 1990, 111, 757-763.
93. Janusz MJ, Hare M. Cartilage degradation by cocultures of transformed macrophage and fibroblast cell lines. A model of metalloproteinase-mediated connective tissue degradation. J Immunol 1993, 150, 1922-1931.
94. Alexander CM, Werb Z. Extracellular matrix degradation. In Cell Biology of Extracellular Matrix, ed. E. D. Hay. Plenum Press, New York, 1991, pp. 255-302.
95. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992, 14, 455-463.
96. Moscatelli D, Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 1988, 948, 67-85.
97. Murphy G, Ward R, Gavrilovic J, Atkinson S. Physiological mechanisms for metalloproteinase activation. Matrix Suppl 1992, 1, 224-230.
98. Kleiner DE Jr. Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 1993, 5, 891-897.
99. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Revs 1993, 73, 161-195.
100. Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells-role in metastasis. Int J Cancer 1982, 30, 669-673.
101. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989, 86, 2632-2636.
102. Vissers MCM. Winterbourn CC. Activation of human neutrophil gelatinase by endogenous serine proteinases. Biochem J 1988, 249, 327-331.
103. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thrombosis & Haemostasis 1995, 74, 429-436.
104. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368, 419-424.
105. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991, 78, 3114-3124.
106. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler 1992, 373, 611-622.
107. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 1992, 11, 291-311.
108. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989, 264, 2185-2188.
109. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985, 100, 86-92.
110. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, Schleuning WD, Blasi F, Appella E, Dano K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990, 265, 6453-6460.
111. Barnathan ES, Kuo A, Kariko K, Rosenfeld L, Murray SC, Behrendt N, Ronne E, Weiner D, Henkin J, Cines DB. Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood 1990, 76, 1795-1806.
112. Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines DB. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 1990, 265, 2865-2872.
113. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990, 9, 467-474.
114. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991, 266, 1926-1933.
115. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991, 30, 1682-1691.
116. Kanalas JJ, Makker SP. Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen. J Biol Chem 1991, 266, 10825-10829.
117. Gonzalez-Gronow M, Gawdi G, Pizzo SV. Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. J Biol Chem 1994, 269, 4360-4366.
118. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986, 103, 2411-2420.
119. 2-macroglobulin. J Biol Chem 1991, 266, 12329-12336.
120. Shih GC, Hajjar KA. Plasminogen and plasminogen activator assembly on the human endothelial cell. Proc Soc Exp Biol & Med 1993, 202, 258-264.
121. Soeda S, Ohki H, Shimeno H, Nagamatsu A. Further characterization of the binding of plasminogen to heparin: evidence for the involvement of lysine residues. Biochim Biophys Acta 1989, 999, 29-35.
122. Edelberg JM, Pizzo SV. Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. Biochemistry 1990, 29, 5906-5911.
123. Edelberg JM, Weissler M, Pizzo SV. Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation. Biochem J 1991, 276, 785-791.
124. Magilavy DB. Animal models of chronic inflammatory arthritis. Clin Orthopaedics Related Res 1990, 259, 38-45.
125. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993, 92, 2675-2682.
126. Perretti M, Flower RJ. Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1. J Immunol 1993, 150, 992-999.
127. Edwards JC, Sedgwick AD, Willoughby DA. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol 1981, 134, 147-156.
128. Li X-K, Matin AF, Suzuki H, Uno T, Yamaguchi T, Harada Y. Effect of protease inhibitor on ischemia-/reperfusion injury of the rat liver. Transplantation 1993, 56, 1331-1336.
129. Okumura Y, Inoue H, Fujiyama Y, Bamba T. Effects of serine protease inhibitors on accumulation of polymorphonuclear leukocytes in the lung induced by acute pancreatitis in rats. J Gastroenterol 1995, 30, 379-386.
130. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989, 56, 1057-1062.
131. Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF, Butcher EC. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 1989, 56, 1063-1072.
132. Doege K, Sasaki M, Horigan E, Hassell JR, Yamada Y. Complete primary structure of the rat cartilage proteoglycan core protein deduced from cDNA clones [published erratum appears in J Biol Chem 1988 Jul 15; 263(20): 10040]. J Biol Chem 1987, 262, 17757-17767.
133. Zimmermann DR, Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 1989, 8, 2975-2981.
134. Zhu L, Hope TJ, Hall J, Davies A, Stern M, Muller-Eberhard U, Stern R, Parslow TG. Molecular cloning of a mammalian hyaluronidase reveals identity with hemopexin, a serum heme-binding protein. J Biol Chem 1994, 269, 32092-32097.
135. Bourguignon J, Diarra-Mehrpour M, Thiberville L, Bost F, Sesbofüé R, Martin J-P. Human pre-α-trypsin inhibitor-precursor heavy chain. cDNA and deduced amino-acid sequence. Eur J Biochem 1993, 212, 771-776.